Proton pump inhibitors market seen reaching $23.42 billion by 2035

Market Research Future projects the global proton pump inhibitors market will grow from $15.02 billion in 2026 to $23.42 billion by 2035, driven by rising GERD cases, wider OTC access and growing hospital use of IV formulations. The forecast points to steady demand across prescription, retail and online channels, with Asia-Pacific expected to be the fastest-growing region.

Why it matters: - Proton pump inhibitors are a core treatment for acid reflux, ulcers and related digestive conditions, so market growth tracks broader demand for everyday and hospital-based gastric acid suppression. - The forecast signals more volume in OTC drugs, prescriptions and IV products, with different pricing dynamics across consumer, retail and inpatient settings. - Wider access could shift treatment earlier, expand self-medication and increase use in critical-care protocols.

What happened: - Market Research Future projected the global proton pump inhibitors market will rise from $15.02 billion in 2026 to $23.42 billion by 2035. - The forecast implies a 5.62% compound annual growth rate during 2026-2035. - The market was estimated at $14.18 billion in 2025. - The report tied growth to broader over-the-counter access, higher GERD prevalence and demand for intravenous delivery systems. - The release was issued June 9, 2026.

The details: - GERD prevalence was estimated at 13.3% of the adult population in a 2024 meta-analysis cited by the report. - The report said processed food consumption, obesity and sedentary lifestyles are lifting GERD rates in urbanizing economies, including India, Brazil and Southeast Asia. - Early-adopter health systems reported about 1.1 million bariatric surgeries worldwide in 2024, up 14% from 2022. - Patients who have sleeve gastrectomy may need high-dose omeprazole for six to 12 months, creating recurring demand. - The U.S. FDA extended OTC status for esomeprazole 20 mg capsules in 2023, after earlier omeprazole OTC switching. - Similar reclassification actions by the UK’s MHRA and Australia’s TGA widened consumer access. - Retail pharmacy chains reported OTC PPI sales volumes rose 11% year over year in 2024. - OTC formulations held about 48.2% of the market in 2025. - Subscription-based acid reflux medication revenue is projected to approach $1.8 billion by 2032 through telehealth platforms including Hims & Hers, Ro and Amazon Pharmacy. - Updated Surviving Sepsis Campaign recommendations support increased IV pantoprazole use in critical care to prevent stress ulcers in mechanically ventilated patients. - Premier Healthcare Alliance procurement data showed IV PPI use rose 18% in U.S. acute-care facilities from 2022 to 2024. - Hospital pharmacies held about 55.7% of distribution in 2025. - Oral products generated $8.83 billion in 2025. - IV formulations are about four to six times more expensive per dose than oral equivalents. - Gastroesophageal reflux disease was the largest indication at about 33.1% share in 2025. - Zollinger-Ellison syndrome was the fastest-growing indication, at 8.72% CAGR. - Peptic ulcer disease accounted for $3.92 billion in 2025. - Other indications, including NSAID-induced gastropathy and Barrett’s esophagus, accounted for $2.14 billion in 2025. - North America held about 39.8% of the market in 2025. - Europe held 26.5% of the market in 2025. - Asia-Pacific was the fastest-growing region, at 7.02% CAGR for 2026-2035. - South America totaled $1.07 billion in 2025. - The Middle East and Africa region is projected to grow at 4.83% CAGR in 2026-2035. - The market is moderately concentrated, with the top five companies holding an estimated 38% to 45% combined revenue share.

Between the lines: - The forecast points to a market shaped by two forces at once: more people needing treatment and more patients buying PPIs without a doctor visit. - Hospital demand is moving toward higher-priced IV products, while consumer growth is being pushed by OTC switches and digital pharmacy models. - The report also suggests the next growth phase may come from formulation innovation, pharmacogenomics and next-generation acid suppression therapies.

What’s next: - The report expects AI-driven personalized acid suppression to influence more than 60% of PPI prescribing decisions in leading markets by 2030. - The NIH’s All of Us Research Program has begun integrating pharmacogenomic PPI data from more than 200,000 participants. - Potassium-competitive acid blockers and dual-action PPI-prokinetic combinations are projected to capture 12% to 15% of the market by 2035. - Sustainability rules in Europe are pushing API makers toward continuous-flow synthesis and lower-waste production. - The report expects generic gastric acid suppression to expand further in Sub-Saharan Africa and Southeast Asia, where penetration remains below 40% of diagnosed patients.

The bottom line: - Proton pump inhibitors remain a mature but still expanding market, with growth coming from broader access, higher GERD burden and a shift toward higher-value hospital and digital channels.